Nicholas Fidelman, Md

This study tests whether adding the immunotherapy drug pembrolizumab to either liver-directed treatments (like ablation or radiation) or peptide receptor radionuclide therapy (PRRT) can shrink or control well-differentiated neuroendocrine tumors that have spread to the liver and …